In addition to galectin-3, other tumor-expressed galectins, such as galectin-9, also suppress T cell activation.228 The galectin-9 receptor, namely, T cell immunoglobulin domain and mucin domain 3 (Tim-3), on Vδ2T cells has recently been shown to suppress their killing capacity by reducing perforin and granzyme B expression.229 A human anti-galectin-9 antibody has been developed for clinical application,230 and its combined use with γδ T cell immunotherapy may be synergistic. Here, LGALS9 is linked to neoplasm.